Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BIO Seeks Weight-Of-Evidence Standard For Drug Approvals

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug reviewers should be able to consider efficacy evidence beyond double-blind, randomized controlled trials, the group says in proposals to stimulate biomedical innovation.

You may also be interested in...



FDA Approval Standards Need To Be Relaxed, Venture Capitalists Say

FDA should accept “a reasonable likelihood of patient benefit” as the appropriate standard for approving therapies for unmet medical needs, the National Venture Capital Association and its Medical Innovation & Competitiveness Coalition contend.

FDA Approval Standards Need To Be Relaxed, Venture Capitalists Say

FDA should accept “a reasonable likelihood of patient benefit” as the appropriate standard for approving therapies for unmet medical needs, the National Venture Capital Association and its Medical Innovation & Competitiveness Coalition contend.

Woodcock Defends Speed Of FDA Reviews, Cites 20 Approvals In First Half Of 2011

As House begins hearings on PDUFA V, industry and venture capitalists say agency policies pre-NDA submission slow drug development.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel